RBC Capital analyst Brian Abrahams upgraded Regeneron to Outperform from Sector Perform with a price target of $1,076, up from $884.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- Regeneron to test Wegovy drug combos to protect muscle mass, Bloomberg says
- Regeneron unit announces multi-national agreement with Medison Pharma
- Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024
- Regeneron’s Eylea in stronger position after IP win, says Goldman Sachs
- Early notable gainers among liquid option names on December 28th